Caveolae: Mining little caves for new cancer targets

Nature Reviews Cancer

Volumn 3, Issue 8, 2003, Pages 571-581

  Carver, Lucy A ^a   Schnitzer, Jan E ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAVEOLIN 1; CHOLESTEROL; GLYCOSPHINGOLIPID; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOTOXIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL MODEL; ANTIGEN RECOGNITION; APOPTOSIS; BREAST CANCER; CANCER; CAVEOLA; CELL GROWTH; CELL MEMBRANE; CELL MEMBRANE TRANSPORT; CELL SURVIVAL; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; ENDOTHELIUM CELL; HETEROZYGOSITY LOSS; HUMAN; IMAGING SYSTEM; LYSOSOME; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TISSUE SPECIFICITY; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM; BIOLOGICAL MODEL; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CAPILLARY PERMEABILITY; CAVEOLAE; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0042386124     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1146     Document Type: Review

References (133)

1. Peters, K. R., Carley, W. W. & Palade, G. E. Endothelial plasmalemmal vesicles have a characteristic striped bipolar surface structure. J. Cell Biol. 101, 2233-2238 (1985).
2. Rothberg, K. G. et al. Caveolin, a protein component of caveolae membrane coats. Cell 68, 673-682 (1992). This paper is one of the first to identify CAV1 as a caveolar-coat protein.
3. Murata, M. et al. VIP21/caveolin is a cholesterol-binding protein. Proc. Natl Acad. Sci. USA 92, 10339-10343 (1995).
4. Schnitzer, J. E., McIntosh, D. P., Dvorak, A. M., Liu, J. & Oh, P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269, 1435-1439 (1995). This paper shows for the first time that caveolae and lipid rafts are biochemically distinct, based on their isolation from two different subcellular fractions derived from the same starting plasma membranes. The subfractionation technology described here makes possible the mapping of tumour-induced endothelial and caveolar targets.
5. Anderson, R. G. & Jacobson, K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296, 1821-1825 (2002).
6. Schnitzer, J. E. In Vascular Endothelium: Physiology, Pathology, and Therapeutic Opportunities (eds Bom, G. V. R. & Schwartz, C. J.) 77-95 (Schattauer, Stuttgart, 1997).
7. s target lipid rafts by default. Mol. Biol. Cell 12, 685-698 (2001).
8. Liu, J., Oh, P., Horner, T., Rogers, R. A. & Schnitzer J. E. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J. Biol. Chem. 272, 7211-7222 (1997).
9. Liu, P., Ying, Y., Ko, Y. G. & Anderson, R. G. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J. Biol. Chem. 271, 10299-10303 (1996).
10. Rizzo, V., Sung, A., Oh, P. & Schnitzer, J. E. Rapid mechanotransduction in situ at the luminal cell surface of vascular endothelium and its caveolae. J. Biol. Chem. 273, 26323-26329 (1998).
11. Rizzo, V., McIntosh, D. P., Oh, P. & Schnitzer, J. E. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J. Biol. Chem. 273, 34724-34729 (1998). This paper provides clear evidence of eNOS residing primarily in the caveolae of vascular endothelium as well as evidence of physiologically significant activation and uncoupling of eNOS from CAV1 by haemodynamic forces.
12. Garcia-Cardena, G. et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J. Biol. Chem. 272, 25437-25440 (1997).
13. Li, S., Couet, J. & Lisanti, M. P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 271, 29182-29190 (1996).
14. Garcia-Cardena, G., Fan, R., Stern, D. F., Liu, J. & Sessa, W. C. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 271, 27237-27240 (1996).
15. Feron, O. et al. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem. 271, 22810-22814 (1996).
16. Park, H. et al. Caveolin-1 regulates shear stress-dependent activation of extracellular signal-regulated kinase. Am. J. Physiol. Heart Circ. Physiol. 278, H1285-H1293 (2000).
17. 2+-calmodulin and caveolin. J. Biol. Chem. 272, 15583-15586 (1997).
18. Bucci, M. et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nature Med. 6, 1362-1367 (2000).
19. Drab, M. et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452 (2001).
20. Razani, B. et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138 (2001). References 19 and 20 comprise the first reports of Cav1-null mice showing that Cav1 and caveolae are involved in various pathways that regulate proliferation, vascular tone and permeability of endothelial cells in vivo.
21. Schnitzer, J. E., Oh, P., Pinney, E. & Allard, J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 127, 1217-1232 (1994).
22. Park, H. et al. Plasma membrane cholesterol is a key molecule in shear stress-dependent activation of extracellular signal-regulated kinase. J. Biol. Chem. 273, 32304-32311 (1998).
23. Montesano, R., Roth, J., Robert, A. & Orci, L. Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 296, 651-653 (1982).
24. Schnitzer, J. E., Allard, J. & Oh, P. NEM inhibits transcytosis, endocytosis, and capillary permeability implication of caveolae fusion in endothelia. Am. J. Physiol. 268, H48-H55 (1995).
25. Schnitzer, J. E. & Oh, P. Aquaporin-1 in plasma membrane and caveolae provides mercury-sensitive water channels across lung endethelium. Am. J. Physiol. 270, H416-H422 (1996).
26. McIntosh, D. P. & Schnitzer, J. E. Caveolae require intact VAMP for targeted transport in vascular endothelium. Am. J. Physiol. 277, H2222-H2232 (1999).
27. Schnitzer, J. E., Oh, P. & McIntosh, D. P. Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science 274, 239-242 (1996). This paper, along with references 38 and 42, establishes that caveolae are not static 'little caves', but rather have the ability to bud from the plasma membrane through GTP hydrolysis mediated by the GTPase dynamin located at the neck of caveolae.
28. Schnitzer, J. E. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv. Drug Del. Rev. 49, 265-280 (2001).
29. Choudhury, A. et al. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109, 1541-1550 (2002).
30. Conrad, P. A., Smart, E. J., Ying, Y. S., Anderson, R. G. & Bloom, G. S. Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubule-independent steps. J. Cell Biol. 131, 1421-1433 (1995).
31. Smart, E. J., Ying, Y. S., Conrad, P. A. & Anderson, R. G. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J. Cell Biol. 127, 1185-1197 (1994).
32. Le, P. U. & Nabi, I. R. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J. Cell Sci. 116, 1059-1071 (2003).
33. Puri, V. et al. Clathrin-dependent and-independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J. Cell Biol. 154, 535-547 (2001).
34. Kartenbeck, J., Stukenbrok, H. & Helenius, A. Endocytosis of simian virus 40 into the endoplasmic reticulum. J. Cell Biol. 109, 2721-2729 (1989).
35. Pelkmans, L., Kartenback, J. & Helenius, A. Caveolar endocytosis of Simian virus 40 reveals a novel two-step vesicular transport pathway to the ER. Nature Cell Biol. 3, 473-483 (2001).
36. Benlimame, N., Le, P. U. & Nabi, I. R. Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Mol. Biol. Cell 9, 1773-1786 (1998).
37. Tran, D., Carpentier, J. L., Sawano, F., Gorden, P. & Orci, L. Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc. Natl Acad. Sci. USA 84, 7957-7961 (1987).
38. Oh, P., McIntosh, D. P. & Schnitzer, J. E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 141, 101-114 (1998).
39. Schnitzer, J. E., Liu, J. & Oh, P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 270, 14399-14404 (1995).
40. Predescu, D., Horvat, R., Predescu, S. & Palade, G. E. Transcytosis in the continuous endothelium of the myocardial microvasculature is inhibited by N-ethylmaleimide. Proc. Natl Acad. Sci. USA 91, 3014-3018 (1994).
41. Stowell, M. H., Marks, B., Wigge, P. & McMahon, H. T. Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring. Nature Cell Biol. 1, 27-32 (1999).
42. Henley, J. R., Krueger, E. W., Oswald, B. J. & McNiven, M. A. Dynamin-mediated internalization of caveolae. J. Cell Biol. 141, 85-99 (1998).
43. Mayor, S., Rothberg, K. G. & Maxfield, F. R. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 264, 1948-1951 (1994).
44. Fujimoto, T. GPI-anchored proteins, glycosphingolipids, and sphingomyelin are sequestered to caveolae only after crosslinking. J. Histochem. Cytochem. 44, 929-941 (1996).
45. Tran, D., Carpentier, J.-L., Sawano, F., Gorden, P. & Orci, L. Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc. Natl Acad. Sci. USA 84, 7957-7961 (1987).
46. Schnitzer, J. E. Update on the cellular and molecular basis of capillary permeability. Trends Cardiovasc. Med. 3, 124-130 (1993).
47. McIntosh, D. P., Tan, X.-Y., Oh, P. & Schnitzer, J. E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl Acad. Sci. USA 99, 1996-2001 (2002). This report is the first to show that molecular heterogeneity of the endothelium and its caveolae allows vascular targeting to achieve rapid tissue-specific delivery and bioefficacy and that caveolae, through transcytosis, might provide a tissue-specific pathway for overcoming key cell barriers to many drug and gene therapies in vivo.
48. Simionescu, M. & Simionescu, N. Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. Cell Biol. Rev. 25, 1-78 (1991).
49. Schnitzer J. E. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am. J. Physiol. 262, H246-H254 (1992).
50. Schnitzer, J. E. & Oh, P. Aquaporin is found on the endothelial cell surface and in caveolae: inhibition of water transport in rat lung in situ. Microcirculation 2, 71 (1995).
51. Brown, D. A. & London, E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275, 17221-17224 (2000).
52. Oh, P. & Schnitzer, J. E. in Cell Biology: A Laboratory Handbook (ed. Celis, J.) 34-36 (Academic Press, Orlando, 1998).
53. Oh, P. & Schnitzer, J. E. Immunoisolation of caveolae with high affinity antibody binding to the oligomeric caveolin cage. Toward understanding the basis of purification. J. Biol. Chem. 214, 23144-23154 (1999).
54. Fra, A. M., Williamson, E., Simons, K. & Parton, R. G. Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J. Biol. Chem. 269, 30746-30748 (1994).
55. Gorodinsky A. & Harris, D. A. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J. Cell Biol. 129, 619-627 (1995).
56. Verkade, P., Harder T., Lafont, F. & Simons, K. Induction of caveolae in the apical plasma membrane of Madin-Darby canine kidney cells. J. Cell Biol. 148, 727-739 (2000).
57. Deckert, M., Ticchioni, M. & Bernard, A. Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases. J. Cell Biol. 133, 791-799 (1996).
58. Makiya, R., Thornell, L. E. & Stigbrand, T. Placental alkaline phosphatase, a GPI-anchored protein, is clustered in clathrin-coated vesicles. Biochem. Biophys. Res. Commun. 183, 803-808 (1992).
59. Sabharaniak, S., Sharma, P., Parton, R. G. & Mayor, S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell 2, 411-423 (2002).
60. Keller, G. A., Siegel, M. W. & Caras, I. W. Endocytosis of glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic pathways. EMBO J. 11, 863-874 (1992).
61. Kitchens, R. L., Wang, P. & Munford, R. S. Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways. J. Immunol. 161, 5534-5545 (1998).
62. Glenney, J. R. Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem. 264, 20163-20166 (1989).
63. Lee, S. W., Reimer, C. L., Oh, P., Campbell, D. B. & Schnitzer, J. E. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16, 1391-1397 (1998).
64. Engelman, J. A. et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272, 16374-16381 (1997). This paper, along with references 63 and 68, reports on the reciprocal relationship between CAV1 expression and cell proliferation and oncogenic transformation.
65. Zhang, W. et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem. 275, 20717-20725 (2000).
66. Fiucci, G., Ravid, D., Reich, R. & Liscovitch, M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21, 2365-2375 (2002).
67. Liu, J., Lee, P., Galbiati, F., Kitsis, R. N. & Lisanti, M. P. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am. J. Physiol. Cell Physiol. 280, C823-C835 (2001).
68. Galbiati, F. et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633-6648 (1998).
69. Razani, B., Schlegel, A., Liu, J. & Lisanti, M. P. Caveolin-1, a putative tumour suppressor gene. Biochem. Soc. Trans. 29, 494-499 (2001).
70. Aoki, T., Nomura, R. & Fujimoto, T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp. Cell Res. 253, 629-636 (1999).
71. Ko, Y. G., Liu, P., Pathak, R. K., Craig, L. C. & Anderson, R. G. Early effects of pp60(v-src) kinase activation on caveolae. J. Cell Biochem. 71, 524-535 (1998).
72. Koleske, A. J., Baltimore, D. & Lisanti, M. P. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl Acad. Sci. USA 92, 1381-1385 (1995).
73. Engelman, J. A. et al. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem. 273, 20448-20455 (1998).
74. Bender F. C., Reymond, M. A., Bron, C. & Quest, A. F. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60, 5870-5878 (2000).
75. Wiechen, K. et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159, 1635-1643 (2001).
76. Wiechen, K. et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158, 833-839 (2001).
77. Zundel, W., Swiersz, L. M. & Giaccia, A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol. Cell Biol. 20, 1507-1514 (2000).
78. Engelman, J. A., Zhang, X. L., Galbiati, F. & Lisanti, M. P. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1,-2, and-3) Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/Tq31). FEBS Lett. 429, 330-336 (1998).
79. Cui, J. et al. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46, 249-256 (2001).
80. Hayashi, K. et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 61, 2361-2364 (2001).
81. Hurlstone, A. F. et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31. 1 in primary tumours and tumour-derived cell lines. Oncogene 18, 1881-1890 (1999).
82. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
83. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992).
84. Oshima, M. et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl Acad. Sci. USA 92, 4482-4486 (1995).
85. Zhao, Y. Y. et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl Acad. Sci. USA 99, 11375-11380 (2002).
86. Lee, H. et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161, 1357-1369 (2002).
87. Williams, T. M. et al. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell 14, 1027-1042 (2003).
88. Mouraviev, V. et al. The role of caveolin-1 in androgen insensitive prostate cancer. J. Urol. 168, 1589-1596 (2002).
89. Tahir S. A. et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882-3885 (2001).
90. Nasu, Y. et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Med. 4, 1062-1064 (1998).
91. Timme, T. L. et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19, 3256-3265 (2000).
92. Li, L. et al. Caveolin-1 mediates testosterone-stimulated survival/ clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386-4392 (2001).
93. Lavie, Y., Fiucci, G. & Liscovitch, M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273, 32380-32383 (1998).
94. Rajjayabun, P. H. et al. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58, 811-814 (2001).
95. Kato, K. et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94, 929-933 (2002).
96. Yang, G. et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4, 1873-1880 (1998).
97. Yang, G., Truong, L. D., Wheeler, T. M. & Thompson, T. C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59, 5719-5723 (1999).
98. Liu, P., Li, W. P., Machleidt, T. & Anderson, R. G. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nature Cell Biol. 1, 369-375 (1999).
99. Lavie, Y., Fiucci, G. & Liscovitch, M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv. Drug Deliv. Rev. 49, 317-323 (2001).
100. Galasko, C. S. & Muckle, D. S. Intrasarcolemmal proliferation of the VX2 carcinoma. Br. J. Cancer 29, 59-65 (1974).
101. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
102. Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
103. Blood, C. H. & Zetter, B. R. Tumor interaction with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032, 89-118 (1990).
104. de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
105. Millauer, B. et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846 (1993).
106. Pertovaara, L. et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 269, 6271-8274 (1994).
107. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. Cancer 2, 795-803 (2002).
108. Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
109. Schubert, W. et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice. J. Biol. Chem. 277, 40091-40098 (2002).
110. Fukumura, D. et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA 98, 2604-2609 (2001). This study used eNos-null mice to show that eNos is involved in Vegf-induced angiogenesis and vascular permeability in vivo.
111. Feng, D., Nagy, J. A., Hipp, J., Dvorak, H. F. & Dvorak, A. M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 183, 1981-1986 (1996).
112. Feng, D. et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6, 23-44 (1999).
113. Vasile, E., Qu, H., Dvorak, H. F. & Dvorak, A. M. Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J. Histochem. Cytochem. 47, 159-167 (1999).
114. Spisni, E. et al. Colocalization prostacyclin (PGI2) synthase-caveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis. Exp. Cell Res. 266, 31-43 (2001).
115. Papetti, M. & Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947-C970 (2002).
116. Liu, J., Wang, X. B., Park, D. S. & Lisanti, M. P. Caveolin-1 expression enhances endothelial capillary tubule formation. J. Biol. Chem. 277, 10661-10668 (2002).
117. Liu, J. et al. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J. Biol. Chem. 274, 15781-15785 (1999).
118. Oh, P., Czarny, M., Huflejt, M. & Schnitzer, J. E. Tumor vascular targeting of caveolae. Proc. Am. Assoc. Cancer Res. 42, A825 (2001).
119. Labrecque, L. et al. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 14, 334-347 (2003).
120. Feng, Y. et al. VEGF-induced permeability increase is mediated by caveolae. Invest. Ophthalmol. Vis. Sci. 40, 157-167 (1999).
121. Schnitzer J. E. Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. 339, 472-474 (1998).
122. Dvorak, H. F., Nagy, J. A. & Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77-85 (1991).
123. Burrows, F. J. & Thorpe, P. E. Vascular targeting: a new approach to the therapy of solid tumors. Pharmacol. Ther. 84, 155-174 (1994).
124. Thrush, G. R., Lark, L. A., Clinchy, B. C. & Vitetta, E. S. Immunotoxins: an update. Ann. Rev. Immunol. 14, 49-71 (1996).
125. Jain, R. K. Barriers to drug delivery in tumors. Sci. Am. 271, 58-65 (1994).
126. Carver, L. A. & Schnitzer, J. E. in Biomedical Aspects of Drug Targeting (eds Muzykantov, V. & Torchilin, B.) 107-128 (Kluwer Academic Publishers, Boston, 2002).
127. Oh, P. et al. Proteomic mapping of tumor neovasculature in vivo for specific targeting and imaging of solid tumors. Proc. Am. Assoc. Cancer Res. 44, A4557 (2003).
128. Yamada, E. The fine structure of the gall bladder epithelium of the mouse. J. Biophys. Biochem. Cytol. 1, 445-458 (1955).
129. Bundgaard, M., Frokjaer-Jensen, J. & Crone, C. Endothelial plasmalemmal vesicles as elements in a system of branching invaginations from the cell surface. Proc. Natl Acad. Sci. USA 76, 6439-6442 (1979).
130. Frokjaer-Jensen, J. The endothelial vesicle system in cryofixed frog mesenteric capillaries analysed by ultrathin serial sectioning. J. Electron Microsc. Tech. 19, 291-304 (1991).
131. Severs, N. J. Caveolae: static inpocketings of the plasma membrane, dynamic vesicles or plain artifact? J. Cell Sci. 90, 341-348 (1988).
132. Rippe, B. & Haraldsson, B. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol. Scand. 131, 411-428 (1987).
133. Garcia-Cardena, G. et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392, 821-824 (1998).